Salvador, JFS, Gimenez-Arnau, AM, de la Fuente, EG, del Castillo, JG, Virtos, AMM, Blanco, IM, Serra-Baldrich, E, Llorens, P. Urticaria in the emergency department: the view of allergy and immunology specialists Reply. EMERGENCIAS. 2021; 33(4)DOI:. PMID:. IF:5.345(Q1/2D).

Magdaleno-Tapial, J, Ortiz-Salvador, JM, Sánchez-Carazo, JL, Hernández-Bel, P, Pérez-Ferriols, A, Santos-Alarcón, S, Sahuquillo-Torralba, A, Pujol-Marco, C, Rivera-Díaz, R, Belinchón-Romero, I, Ruiz-Geneao, D, Romero-Maté, A, Ruiz-Villaverde, R, Ferrán-Farrés, M, Gallardo-Hernández, F, Almenara-Blasco, M, Alonso-Suárez, J, González-Cantero, A, Martínez-Lorenzo, E, Fernández-Armenteros, JM, de Alcázar-Viladomiu, E, Garcia-Latasa, J, Rocamora-Durant, V, Ara-Martín, M, Mateu-Puchades, A, Llamas-Velasco, M, Vilarrasa-Rull, E, Velasco-Pastor, M, de la Cueva-dobao, P, Carrascosa-Carrillo, JM, Martorell-Calatayud, A. Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain. Dermatologic Therapy. 2024; 2024DOI:10.1155/2024/5528484. PMID:. IF:3.400(Q1/2D).

Mercader-García, P, Silvestre, JF, Navarro-Triviño, FJ, Giménez-Arnau, AM, Pastor-Nieto, MA, Cordoba-Guijarro, S, Melé-Ninot, G, Tous-Romero, F, González-Pérez, R, Ruiz-González, I, Sánchez-Pérez, J, Gática-Ortega, ME, Sánchez-Pedreño, P, Miquel-Miquel, J, Ortiz-Frutos, J, Carrascosa, JM, Serra-Baldrich, E, Sanz-Sanchez, T, Soria-Aledo, V, Carrillo, A, Borrego, L. A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight. CONTACT DERMATITIS. 2024; 91(3)DOI:10.1111/cod.14639. PMID:38965446. IF:4.600(Q1/1D).

Chovatiya, R, Armstrong, A, Kircik, L, Puig, L, Kirchhof, MG, Torres, T, Binamer, Y, Duarte, G, Akmaz, B, Dossenbach, M, Gallo, G, Yang, C, Seminario-Vidal, L, Ding, YX, Silverberg, JI. Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison. Dermatology and Therapy. 2026; 16(2)DOI:10.1007/s13555-025-01620-x. PMID:41420795. IF:4.200(Q1/1D).

Torres, T, Sood, S, Yilmaz, O, Vender, RB, Prajapati, VH, Puig, L, Megna, M, Marzano, AV, Gisondi, P, Carrascosa, JM, Dauden, E, Llamas-Velasco, M, Balato, A, Leal, BG, Prignano, F, Bellinato, F, Silvi, G, Di Brizzi, EV, Potestio, L, Carrera, CG, López-Ferrer, A, Del-Alcazar, E, Mufti, A, Maul, LV, Piaserico, S, Maul, JT, Yeung, JS. Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study. Dermatology and Therapy. 2026; 16(2)DOI:10.1007/s13555-026-01653-w. PMID:41575604. IF:4.200(Q1/1D).

Díaz, JM, Alarcon, SS, Romero, IB, Apetrei, LS, Fernández, LG, Ramos, FJM, Alberola, FT, Martínez, MAB, Ruiz, AB, Rodríguez, OB, Ruiz-Villaverde, R, González, MC, Farrés, MF, Puchades, AM, Tapial, JM, Rull, EV, Montalvo, SM. Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish Study. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2026; 67(1)DOI:10.1111/ajd.70012. PMID:41347368. IF:1.800(Q3/6D).